BLU-808

Overview

• Priority class: KIT
• Mechanistic bucket: KIT-targeted mast-cell pathway program
• Sponsor: Blueprint Medicines (acquired by Sanofi)
• Development focus: Active clinical development represented in current raw-source layer
• Indications represented in current raw sources: Chronic Inducible Urticaria, Chronic Spontaneous Urticaria

Strategy readout

• Headline: Broad early wild-type KIT exploration across CSU and CIndU, now carried inside Sanofi after the Blueprint acquisition.
• Current strategic read: The current registry footprint is still thin, but the visible study design suggests BLU-808 remains a breadth-first wild-type KIT urticaria program spanning both spontaneous and inducible disease. The corporate context changed materially once Sanofi completed the Blueprint Medicines acquisition in July 2025, so future BLU-808 decisions should be read as Sanofi portfolio prioritization rather than a standalone Blueprint narrowing decision.
• Highest visible phase in current registry: Phase 2
• Strategy confidence in current local layer: Medium

Why this looks like the strategy

• Only one CT.gov-linked study is visible in the current local layer, but it explicitly spans both CIndU and CSU.
• The current study stack still looks like early cross-phenotype signal seeking rather than a mature registrational build.
• The cached Sanofi completion press release explicitly brings Blueprint's KIT-driven pipeline into Sanofi and assigns BLU-808 milestone value in the deal structure, which supports treating the asset as part of Sanofi's immunology portfolio context rather than only a historical Blueprint program.

What to watch next

• Whether later Sanofi pipeline materials show a clearer lead urticaria phenotype or narrower development focus for BLU-808.
• Whether sponsor-facing trial materials and future disclosures start reflecting Sanofi ownership directly instead of legacy Blueprint branding.

Operational study design view

Study Inventory

Completed / historical studies

• None in current registry

Active / recruiting studies

• NCT06931405 - Phase 2; RECRUITING; Chronic Inducible Urticaria, Chronic Spontaneous Urticaria

Other registry entries

• None in current registry

Evidence Coverage

• CT.gov trials in registry: 1
• Sponsor artifacts in registry: 5
• Primary publications in registry: 0
• Supporting publications in registry: 0
• Publication status: no_pubmed_hits
• Publication summary: No PubMed hits were returned for BLU-808 AND urticaria in this pass.

Primary publications

• No primary publications currently linked in the registry

Supporting evidence

• No supporting publications currently listed
• Sponsor artifact: Core programs page (Blueprint Medicines)
• raw/sponsors/kit/blu-808/core-programs-page.html
• raw/sponsors/kit/blu-808/core-programs-page.md
• Sponsor artifact: AAAAI WAO 2025 publications page (Blueprint Medicines)
• raw/sponsors/kit/blu-808/aaaai-wao-2025-publications-page.html
• raw/sponsors/kit/blu-808/aaaai-wao-2025-publications-page.md
• Sponsor artifact: AAAAI WAO 2025 BLU-808 WT KIT poster (Blueprint Medicines)
• raw/sponsors/kit/blu-808/aaaai-wao-2025-blu-808-wt-kit-poster.pdf
• raw/sponsors/kit/blu-808/aaaai-wao-2025-blu-808-wt-kit-poster.txt
• raw/sponsors/kit/blu-808/aaaai-wao-2025-blu-808-wt-kit-poster.md
• Sponsor artifact: AAAAI 2024 BLU-808 WT KIT poster (Blueprint Medicines)
• raw/sponsors/kit/blu-808/aaaai-2024-blu-808-wt-kit-poster.pdf
• raw/sponsors/kit/blu-808/aaaai-2024-blu-808-wt-kit-poster.txt
• raw/sponsors/kit/blu-808/aaaai-2024-blu-808-wt-kit-poster.md
• Sponsor artifact: Sanofi completes acquisition of Blueprint Medicines (Sanofi)
• raw/sponsors/kit/blu-808/sanofi-completes-acquisition-of-blueprint-medicines.pdf
• raw/sponsors/kit/blu-808/sanofi-completes-acquisition-of-blueprint-medicines.txt
• raw/sponsors/kit/blu-808/sanofi-completes-acquisition-of-blueprint-medicines.md

Interpretation

• Verified facts: the current v2 registry tracks 1 CT.gov entries for this program and links them conservatively to sponsor and publication evidence where explicit identifiers are available.
• Interpretation: this program is currently supported mainly by CT.gov and/or sponsor-source evidence, with weaker direct manuscript coverage in the local cache.
• Open questions:
• Several sponsor artifacts remain program-level because no explicit study identifier was captured in cached metadata.

Provenance

• Primary source(s):
• ../inventories/source_registry.json
• ../inventories/source_registry.md
• Supporting source(s):
• ../inventories/ctgov_priority_trials.json
• ../inventories/publication_priority_curation.json
• ../inventories/sponsor_priority_sources.json
• Last verified: 2026-04-08
• Verification status: Partial

Change Log

• 2026-04-08: Generated or refreshed this program page from the v2 source registry and local source caches.